Molecular Tumour Board
The VCCC Alliance Molecular Tumour Board (MTB) is a multidisciplinary style forum that provides opinion on the clinical implications of molecular pathology test results of tumours.
Each case is discussed on an individual, de-identified basis. Most MTB meetings also feature an educational presentation.
Discussion and assessment of molecular pathology results
The MTB is convened by Dr Stephen Luen, Peter MacCallum Cancer Centre, with an expert group comprised of clinical and scientific staff from across the VCCC Alliance providing opinion on each case.
The MTB educational and research presentations provide an excellent opportunity to learn more about personalised medicine. CPD points are available for meeting attendance. The MTB welcomes referrals from any clinician or multi-disciplinary team from VCCC Alliance members and collaborators.
Clinicians, scientists and students (from any organisation) are welcome to attend the meetings, which are held on Fridays 2.45pm - 4.00pm.
If you would like to receive meeting agendas, be added to the mailing list, or have other enquiries, please contact Emma Petrie, Program Manager - Translational Research, firstname.lastname@example.org
In accordance with our COVID-19 precautions the MTB will be convened online until further notice.
Friday, 17 September, 2.45-4pm
“CODEC – CIRCULATING TUMOUR DNA in Endometrial Cancer"
- Dr Rachel Delahunty, Medical Oncologist, Peter MacCallum Cancer Centre
“MBD4 deficiency in a patient with AML and colonic polyposis: an emerging multiorgan cancer predisposition syndrome"
- Dr Lucy Fox, Clinical Haematologist, Peter MacCallum Cancer Centre
- Dr Georgie Ryland, Medical Scientist, Peter MacCallum Cancer Centre and University of Melbourne Centre for Cancer Research
Clinical case presentation
Future dates and speakers to be confirmed for 2021
We welcome cases from clinicians whose patients have had molecular pathology testing performed as part of clinical care or research. Experts will provide advice and opinion regarding the clinical implications of the molecular pathology findings. Wherever possible, referring clinicians will also be advised on appropriate available clinical trials.
To submit a case to the MTB, please complete the MTB case form template and send via email to Emma Petrie, Program Manager - Translational Research, email@example.com